DDInter179 DDInter1376
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Bendroflumethiazide {u} (Compound) resembles {v} (Compound) Benzthiazide
Bendroflumethiazide {u} (Compound) resembles {v} (Compound) Cyclothiazide
Bendroflumethiazide {u} (Compound) treats {v} (Disease) hypertension
Bendroflumethiazide {u} (Compound) binds {v} (Gene) CA4
Bendroflumethiazide {u} (Compound) upregulates {v} (Gene) MAL
Bendroflumethiazide {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Bendroflumethiazide {u} (Compound) downregulates {v} (Gene) KIF20A
Bendroflumethiazide {u} (Compound) causes {v} (Side Effect) Hypotension
Bendroflumethiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clidinium
Bendroflumethiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyoscyamine
Bendroflumethiazide (Compound) resembles Benzthiazide (Compound)
Bendroflumethiazide (Compound) resembles Cyclothiazide (Compound)
Bendroflumethiazide (Compound) treats hypertension (Disease)
Bendroflumethiazide (Compound) binds CA4 (Gene)
Bendroflumethiazide (Compound) upregulates MAL (Gene)
Bendroflumethiazide (Compound) is included by Increased Diuresis (Pharmacologic Class)
Bendroflumethiazide (Compound) downregulates KIF20A (Gene)
Bendroflumethiazide (Compound) causes Hypotension (Side Effect)
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Clidinium
Bendroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine